Table of contents

• Trial overview
• Who was studied
• Study design and phase
• What was measured
• Trial status and size
• What this means for patients

Trial overview

The available clinical trial studied Linperlisib in people with relapsed or refractory peripheral T/NK cell lymphoma and cutaneous T cell lymphoma.^[1] The study title also lists Linperlisib as YY-20394.^[1] This trial was designed to see how well the treatment worked in these hard-to-treat cancers.^[1]

Who was studied

The trial focused on adults with lymphoma that had come back after treatment or had not responded to earlier treatment.^[1] In simple terms, “relapsed” means the disease returned, and “refractory” means it did not improve with treatment.^[1] Two disease groups were included: peripheral T/NK cell lymphoma, also called PTCL, and cutaneous T cell lymphoma, also called CTCL.^[1]

Study design and phase

This was an interventional study, which means the research team gave a planned treatment rather than only observing patients.^[1] It was a Phase 2 trial, a stage that usually looks at whether a treatment shows signs of benefit and continues to collect safety information.^[1] The study was completed and enrolled 107 participants.^[1]

What was measured

The main endpoint was overall response rate, often shortened to ORR.^[1] ORR combines complete response and partial response, meaning the cancer either disappeared on testing or became smaller.^[1] For PTCL, the response was measured from the start of treatment to the first documented response using Lugano 2014 Response Criteria for non-Hodgkin lymphoma.^[1] For CTCL, response was based on the Olsen Global Response Score.^[1] The brief summary says an Independent Radiology Review Committee reviewed the results, which means outside experts checked scan findings separately.^[1]

Trial status and size

The trial status is listed as Completed.^[1] It included 107 participants, which gives a moderate-sized group for a Phase 2 cancer study.^[1] The available data do not provide extra details on secondary endpoints beyond the main response measure.^[1]

What this means for patients

Based on the trial record, Linperlisib has been studied in a specific group of patients with difficult lymphoma types that had already resisted or returned after treatment.^[1] The research goal was not broad use in many diseases, but a focused test in PTCL and CTCL.^[1] Because the study was Phase 2, it was mainly about learning whether the treatment shows enough activity to justify further research.^[1]